9 Statement of the problem In the U.S., among the 3.5-8 million women with IC symptoms, only 9.7% have received a diagnosis of IC
The compound described is not approved for human therapeutic use absent a controlled clinical trial
BPC-157 primarily works at the genetic level to increase actin production and growth factor expression, while TB-500 functions as an actin-binding protein that facilitates cellular movement and migration
Here are some potential causes of IC: Defect in the bladder lining: One theory suggests that the bladder epithelium, a thin layer of cells that lines the bladder, is damaged
Dihexas unique chemical structure helps it penetrate deeply into the central nervous system, potentially making it a candidate for addressing cognitive decline
In the adjusted logistic regression model, the strongest factor associated with non-OAC was CHA 2 DS 2 -VA score of 0 points (OR 7.056, [95%CI, 4.441-11.211)], followed by a score of 1 point (OR 3.035 [95% CI, 2.448-3.762])
